| Term 
 | Definition 
 
        | rapid onset or change in HF symptoms and signs, requiring urgent treatment |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | rapid onset, usually secondary to other acute cardiac causes |  | 
        |  | 
        
        | Term 
 
        | acute decompensated heart failure (ADHF) |  | Definition 
 
        | worsening symptoms in patients with preexisting HF |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | evidence of tissue hypoperfusion induced by HF after correction of preload |  | 
        |  | 
        
        | Term 
 
        | BNP - better correlated with left ventricular end diastolic pressure NT-proBNP - a byproduct of BNP synthesis and is secreted in proportion to BNP
 |  | Definition 
 
        | synthesized in response to ventricular stretch cause vasodilation -> counteracts vasoconstriction
 induce Na excretion -> counteracts Na/water retention
 |  | 
        |  | 
        
        | Term 
 
        | cardiac causes:  myocaridal ischemia or infarction, arrhythmias, pulmonary embolism, vavlular disease, uncontrolled HTN infection
 anemia
 thyroid disease (hyperthyroidism)
 **non-adherence:  medications, dietary restrictions**
 medication induced: non DHP CCB are contraindicated in AHF
 |  | Definition 
 
        | precipitating factors of AHF |  | 
        |  | 
        
        | Term 
 
        | Na/water retention:  **NSAIDS**, thiazolidinediones, steroids, drugs with high Na content negative inotropes:  antiarrhythmics, B blockers, **non DHP CCB**, alcohol, cocaine
 |  | Definition 
 
        | medications that can cause AHF |  | 
        |  | 
        
        | Term 
 
        | symptoms:  dsypnea/DOE, orthopnea/PND, cough, peripheral edema, abdominal swelling, abdominal pain/nausea/bloating, weight gain signs:  rales/crackles, hypoxemia, JVD, HJR, pleural effusion/pulmonary congestion on CXR, hepatomegaly/ascites
 |  | Definition 
 
        | clinical presentation of volume overload |  | 
        |  | 
        
        | Term 
 
        | symptoms:  sleepiness, confusion, cold and clammy skin, cold extremities, decreased urine output signs:  cyanosis, poor capillary refill, weak extremity pulses, hypotension (SBP<90), tachycardia (HR>90), acidosis, increased BUN/SrCr (decreased kidney perfusion), increased LFT
 |  | Definition 
 
        | clinical presentation of hypoperfusion |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | uncertain diagnosis (LV dysfunction, pulmonary embolism, renal dysfunction) |  | Definition 
 
        | BNP 100-400 NT proBNP 400-2000
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | arterial line: continuous arterial BP monitoring, frequent ABG draws central venous catheter:  delivers fluid and drugs into central circulation, measures central venous pressure (CVP), measures venous oxygen saturation
 pulmonary artery catheter (Swan-Ganz):  measures and calculates hemodynamic parameters, such as left ventricular pressure, fallen out of favor due to high complication rates
 |  | Definition 
 
        | invasive monitoring: arterial line
 central venous catheter
 pulmonary artery catheter (Swan-Ganz)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | pulmonary capillary wedge pressure (PCWP) estimates ( ) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cardiac index is CO divided by BSA.  it is standardized so comparisons can be made.  Tells you if a patient is ( ) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | systemic vascular resistance estimates ( ) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mean arterial pressure (MAP) evaluates ( ) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | at what point does a PCWP reading indicate AHF? |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | at what point does a cardiac index reading indicate HF? |  | 
        |  | 
        
        | Term 
 
        | refractory HF symptoms refractory hypotension (SBP < 80)
 worsening renal function during therapy
 concurrent cardiac and pulmonary disease
 hypoxia in need of intubation
 |  | Definition 
 
        | patients with these conditions will be considered for invasive monitoring |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | therapy used if the patient is fluid overloaded [image]
 first line treatment of symptoms due to mild to moderate fluid retention
 if once daily dosing at home, double the dose and give as IV bolus OR
 if on multiple doses at home, total daily dose given as IV bolus
 if no adequate diuresis, double the subsequent doses until achieved
 try to maintain a net loss of 1L
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | lack of or inadequate increase in urine output despite increasing diuretic dose decreased intravascular volume -> increased RAAS and SNS
 decreased renal perfusion due to low CO
 Na overload
 |  | 
        |  | 
        
        | Term 
 
        | Na and water restriction (2g of Na and 2L of water) increase diuretic dosing frequency or give as continuous infusion
 combine with another diuretic
 may consider cautious fluid replacement if intravascularly dry
 may consider adding inotrope if hypoperfusion is suspected
 |  | Definition 
 
        | how to overcome diuretic resistance |  | 
        |  | 
        
        | Term 
 
        | vasodilators venous vasodilators: nitroglycerin, nitroprusside, nesiritide
 arterial vasodilators: nitroprusside, nesiritide
 |  | Definition 
 
        | should be considered in patients with persistent symptoms despite aggressive loop diuretics and have SBP > 110-120 mmHg (avoid in SBP < 90) |  | 
        |  | 
        
        | Term 
 
        | nitroglycerin: tolerance nitroprusside:  cyanide or thiocyanate accumulation
 nesiritide:  increased risk of worsening renal function, increased risk of death
 |  | Definition 
 
        | adverse effects of vasodilators |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | therapy used if the patient is intravascularly dry [image]
 however, further increase in preload in a failing heart may exacerbate the condition
 if unsure of preload and the patient has signs of hypoperfusion (cardiogenic shock) this may be attempted
 if no improvement in BP, inotrope should be considered
 |  | 
        |  | 
        
        | Term 
 
        | dobutamine dopamine
 milrinone
 |  | Definition 
 
        | ( ) is the inotrope of choice.  concurrent use of BB should be DC'd ( ) is indicated in SBP <90 or symptothetic hypotension, despite dobutamine
 ( ) is indicated for low CO, but SBP is > 90 and on concurrent BB.
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | therapy reserved for sicker patients signs of hypoperfusion despite vasodilators and/or diuretics
 unresponsive/intolerant to vasodilator (add to or replace vasodilators)
 severe LV systolic dysfunction (low EF)
 cardiogenic shock
 may allow continued diuretic +/- vasodilator therapy
 lowest possible dose for the shortest possible duration
 continuous monitoring of BP and EKG
 used most in subset 4 patients (wet and cold)
 |  | 
        |  | 
        
        | Term 
 
        | vasopressors adrenergic agonists
 EPI and NE
 |  | Definition 
 
        | only use in cardiogenic shock with severe hypotension (SBP < 70) may exacerbate high SVR and further decrease organ perfusion
 |  | 
        |  | 
        
        | Term 
 
        | for fluid overload patient with inadequate response to diuretic therapy |  | Definition 
 
        | ultrafiltration filters the blood in order to remove excess Na and water. It pulls off more fluid than IV diuretics without effecting BP, HR, or electrolytes.
 when is it used?
 |  | 
        |  |